Protara Therapeutics Statistics
Total Valuation
TARA has a market cap or net worth of $127.67 million. The enterprise value is $50.91 million.
Important Dates
The next estimated earnings date is Wednesday, March 12, 2025, before market open.
| Earnings Date | Mar 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TARA has 34.32 million shares outstanding. The number of shares has increased by 46.80% in one year.
| Current Share Class | 34.32M |
| Shares Outstanding | 34.32M |
| Shares Change (YoY) | +46.80% |
| Shares Change (QoQ) | +5.16% |
| Owned by Insiders (%) | 3.08% |
| Owned by Institutions (%) | 66.54% |
| Float | 25.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 1.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.85, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.85 |
| Quick Ratio | 9.43 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.97% and return on invested capital (ROIC) is -33.90%.
| Return on Equity (ROE) | -52.97% |
| Return on Assets (ROA) | -31.42% |
| Return on Invested Capital (ROIC) | -33.90% |
| Return on Capital Employed (ROCE) | -53.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.56M |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.77% in the last 52 weeks. The beta is 1.63, so TARA's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | -6.77% |
| 50-Day Moving Average | 5.04 |
| 200-Day Moving Average | 3.02 |
| Relative Strength Index (RSI) | 33.05 |
| Average Volume (20 Days) | 270,445 |
Short Selling Information
The latest short interest is 4.20 million, so 12.23% of the outstanding shares have been sold short.
| Short Interest | 4.20M |
| Short Previous Month | 4.40M |
| Short % of Shares Out | 12.23% |
| Short % of Float | 16.27% |
| Short Ratio (days to cover) | 11.90 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -45.88M |
| Pretax Income | -40.69M |
| Net Income | -42.05M |
| EBITDA | -45.53M |
| EBIT | -45.88M |
| Earnings Per Share (EPS) | -$2.53 |
Full Income StatementBalance Sheet
The company has $81.50 million in cash and $4.74 million in debt, giving a net cash position of $76.76 million or $2.24 per share.
| Cash & Cash Equivalents | 81.50M |
| Total Debt | 4.74M |
| Net Cash | 76.76M |
| Net Cash Per Share | $2.24 |
| Equity (Book Value) | 81.79M |
| Book Value Per Share | 3.96 |
| Working Capital | 76.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$35.20 million and capital expenditures -$63,000, giving a free cash flow of -$35.26 million.
| Operating Cash Flow | -35.20M |
| Capital Expenditures | -63,000 |
| Free Cash Flow | -35.26M |
| FCF Per Share | -$1.03 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |